Việc giảm số ca sốt rét trên lâm sàng lệ thuộc nhiều vào khả năng ngăn ngừa muỗi Anopheles nhiễm mầm bệnh đốt người. Các chiến lược phòng chống vector sử dụng màn tẩm hóa chất tồn lưu kéo dài(LLINs_Long-Lasting Insecticidal Nets) và phun tồn lưu trong nhà (IRS_Indoor Residual Spraying) bằng các hóa chất đã góp phần làm giảm đáng kể tỷ lệ mắc mới sốt rét tại nhiều quốc gia có bệnh lưu hành, đặc biệt ở vùng sa mạc Sahara.

Ivermectin (IVM) là một công cụ tiềm năng phòng chống vector mới (a potential new vector control tool) để làm giảm lan truyền sốt rét. Khi các con muỗi đốt máu có chứa thuốc IVM sẽ làm cho chúng giảm thời gian hay tuổi thọ muỗi, điều này có nghĩa là chúng ít có thể sống đủ dài để hoàn thành chu kỳ sporogony và đủ nhiễm bệnh.

Hình 1. Lợi điểm và thách thức, định hướng nghiên cứu tương lai có sử dụng ivermectine để giảm lan truyền sốt rét
|Nguồn: https://www.sciencedirect.com/science/article/pii/S0001706X23001602

Hình 2. Một mô hình nghiên cứu cho thấy Ivermectine làm giảm ổ chứa ký sinh trùng trong muỗi
|Nguồn: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1802-3

Hình 3. Hiệu lực MDA ivermectin về lý thuyết dựa trên 3 thông số chính:Nồng độ trong huyết tương
có hiệu quả liên kết trực tiếp với tính nhạy đặc hiệu của IVMtrên các vector tại chỗ. RME làm giảm chuyển hóa hóa thải trừ
|Nguồn: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1802-3

Hình 4. Mô hình lý thuyết sử dụng IVM trên người và/ hoặc động vật nuôi bán chăn thả theo hành vi của vector ưu thế.
(a) Hình 4 màu minh họa mục đích chỉ trên người ở ngoài nhà, vì thế IVM nên cho hư một biện pháp bổ sung. 
(b) cho thấy làm thế nào sử dụng thuốc IVM trong một khuôn viên đặc biệt thiết kế theo hành vi của các vector chính.
|Nguồn: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1802-3

Hình 5. Mô hình giữa chính sách, kinh doanh liên quan đến phát triển thuốc IVM như một công cụ bổ sung cho giảm lan truyền sốt rét.
Nguồn: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1803-2

Hình 6. Một mô hình thử nghiệm sử dụng IVM trên gia súc để làm giảm lan truyền bệnh sốt rét
tại thực địa hẹp và cả tại môi trường thôn buôn.
Nguồn: https://www.ajtmh.org/view/journals/tpmd/104/6/article-p2165.xml

1.Fighting malaria with ivermectin: a novel malaria control tool.Teboh-Ewungkem MI, Ngwa GA.Lancet Infect Dis. 2020 Apr;20(4):394-395. doi: 10.1016/S1473-3099(19)30691-7. Epub 2020 Jan 13.PMID: 31948766.

2.Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia.Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, Mohammed N, Kandeh B, Smit MR, Slater H, Peeters Grietens K, Broekhuizen H, Bousema T, Drakeley C, Lindsay SW, Achan J, D'Alessandro U.Lancet Infect Dis. 2022 Apr;22(4):519-528. doi: 10.1016/S1473-3099(21)00557-0. Epub 2021 Dec 15.PMID: 34919831

3.Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, Ter Kuile FO.Lancet Infect Dis. 2018 Jun;18(6):615-626. doi: 10.1016/S1473-3099(18)30163-4. Epub 2018 Mar 27.PMID: 29602751 Clinical Trial.

4.Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial.Soumare HM, Dabira ED, Camara MM, Jadama L, Gaye PM, Kanteh S, Jawara EA, Njie AK, Sanneh F, Ndiath MO, Lindsay SW, Conteh B, Ceesay S, Mohammed N, Ooko M, Bradley J, Drakeley C, Erhart A, Bousema T, D'Alessandro U.Parasit Vectors. 2022 Nov 17;15(1):435. doi: 10.1186/s13071-022-05557-4.PMID: 36397132 

5.A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.The Ivermectin Roadmappers; Billingsley P, Binka F, Chaccour C, Foy B, Gold S, Gonzalez-Silva M, Jacobson J, Jagoe G, Jones C, Kachur P, Kobylinski K, Last A, Lavery JV, Mabey D, Mboera D, Mbogo C, Mendez-Lopez A, Rabinovich NR, Rees S, Richards F, Rist C, Rockwood J, Ruiz-Castillo P, Sattabongkot J, Saute F, Slater H, Steer A, Xia K, Zullinger R.Am J Trop Med Hyg. 2020 Feb;102(2s):3-24. doi: 10.4269/ajtmh.19-0620.PMID: 31971144 

6.Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.Graves PM, Gelband H, Garner P.Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152. doi: 10.1002/14651858.CD008152.pub4.PMID: 25693791 

7.Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults - a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial.Ekoka Mbassi D, Mombo-Ngoma G, Held J, Okwu DG, Ndzebe-Ndoumba W, Kalkman LC, Ekoka Mbassi FA, Pessanha de Carvalho L, Inoue J, Akinosho MA, Dimessa Mbadinga LB, Yovo EK, Mordmüller B, Kremsner PG, Adegnika AA, Ramharter M, Zoleko-Manego R.EBioMedicine. 2023 Nov;97:104814. doi: 10.1016/j.ebiom.2023.104814. Epub 2023 Oct 13.

8.A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.Ominde KM, Kamau Y, Karisa J, Muturi MN, Kiuru C, Wanjiku C, Babu L, Yaah F, Tuwei M, Musani H, o­ndieki Z, Muriu S, Mwangangi J, Chaccour C, Maia MF.Malar J. 2023 Sep 30;22(1):291. doi: 10.1186/s12936-023-04718-9.PMID: 37777725.

9.Does ignoring transmission dynamics lead to underestimation of the impact of interventions against mosquito-borne disease?Cavany S, Huber JH, Wieler A, Tran QM, Alkuzweny M, Elliott M, España G, Moore SM, Perkins TA.BMJ Glob Health. 2023 Aug;8(8):e012169. doi: 10.1136/bmjgh-2023-012169.PMID: 37652566 

10.Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control o­n the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones RT, Ndiath MO, Dit Massire Soumare H, Mabey D, Nante EJ, Martins C, Logan JG, Slater H, Drakeley C, D'Alessandro U, Rodrigues A, Last AR.BMJ Open. 2023 Jul 7;13(7):e072347. doi: 10.1136/bmjopen-2023-072347.PMID: 37419638 

11.The oral repellent - science fiction or common sense? Insects, vector-borne diseases, failing strategies, and a bold proposition.Bauer IL.Trop Dis Travel Med Vaccines. 2023 Jun 28;9(1):7. doi: 10.1186/s40794-023-00195-9.PMID: 37381000 

12.Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, Aljayyoussi G, Bousema T, Burrows J, D'Alessandro U, Alout H, Ter Kuile FO, Walker PGT, Ghani AC, Smit MR.Lancet Infect Dis. 2020 Apr;20(4):498-508. doi: 10.1016/S1473-3099(19)30633-4. Epub 2020 Jan 13.

13.Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults - a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial. Ekoka Mbassi D, Mombo-Ngoma G, Held J, Okwu DG, Ndzebe-Ndoumba W, Kalkman LC, Ekoka Mbassi FA, Pessanha de Carvalho L, Inoue J, Akinosho MA, Dimessa Mbadinga LB, Yovo EK, Mordmüller B, Kremsner PG, Adegnika AA, Ramharter M, Zoleko-Manego R.EBioMedicine. 2023 Nov;97:104814. doi: 10.1016/j.ebiom.2023.104814. Epub 2023 Oct 13.PMID: 37839134 

14.A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.Ominde KM, Kamau Y, Karisa J, Muturi MN, Kiuru C, Wanjiku C, Babu L, Yaah F, Tuwei M, Musani H, o­ndieki Z, Muriu S, Mwangangi J, Chaccour C, Maia MF.Malar J. 2023 Sep 30;22(1):291. doi: 10.1186/s12936-023-04718-9.PMID: 37777725.

15.Does ignoring transmission dynamics lead to underestimation of the impact of interventions against mosquito-borne disease?Cavany S, Huber JH, Wieler A, Tran QM, Alkuzweny M, Elliott M, España G, Moore SM, Perkins TA.BMJ Glob Health. 2023 Aug;8(8):e012169. doi: 10.1136/bmjgh-2023-012169.PMID: 37652566 

16.Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control o­n the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones RT, Ndiath MO, Dit Massire Soumare H, Mabey D, Nante EJ, Martins C, Logan JG, Slater H, Drakeley C, D'Alessandro U, Rodrigues A, Last AR.BMJ Open. 2023 Jul 7;13(7):e072347. doi: 10.1136/bmjopen-2023-072347.PMID: 37419638.

17.The oral repellent - science fiction or common sense? Insects, vector-borne diseases, failing strategies, and a bold proposition.Bauer IL.Trop Dis Travel Med Vaccines. 2023 Jun 28;9(1):7. doi: 10.1186/s40794-023-00195-9.PMID: 37381000. 

18.Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria.Eneanya OA, Reimer LJ, Fischer PU, Weil GJ.Int Health. 2023 Sep 1;15(5):566-572. doi:0.1093/inthealth/ihad029.PMID: 37096453  

19.Perennial malaria chemoprevention with and without malaria vaccination to reduce malaria burden in young children: a modelling analysis.Runge M, Stahlfeld A, Ambrose M, Toh KB, Rahman S, Omoniwa OF, Bever CA, Oresanya O, Uhomoibhi P, Galatas B, Tibenderana JK, Gerardin J.Malar J. 2023 Apr 24;22(1):133. doi: 10.1186/s12936-023-04564-9.PMID: 37095480 

20.Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria.Foy BD, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson CL, Kittelson J, Slater HC, Bousema T, Da O, Coulidiaty AGV, Colt M, Wade M, Richards K, Some AF, Dabire RK, Parikh S.JMIR Res Protoc. 2023 Mar 20;12:e41197. doi: 10.2196/41197.PMID: 36939832  

21.Conservation of Importin α Function in Apicomplexans: Ivermectin and GW5074 Target Plasmodium falciparum Importin α and Inhibit Parasite Growth in Culture. Walunj SB, Wang C, Wagstaff KM, Patankar S, Jans DA.Int J Mol Sci. 2022 Nov 11;23(22):13899. doi: 10.3390/ijms232213899.PMID: 36430384

22.The use of Ivermectin for the treatment of COVID-19: Panacea or enigma? o­nyeaka H, Tamasiga P, Agbara JO, Mokgwathi OA, Uwishema O.Clin Epidemiol Glob Health. 2022 Jul-Aug;16:101074. doi: 10.1016/j.cegh.2022.101074. Epub 2022 Jun 8.PMID: 35694631 

23.Potential impact of 5 years of ivermectin mass drug administration o­n malaria outcomes in high burden countries. Marathe A, Shi R, Mendez-Lopez A, Hu Z, Lewis B, Rabinovich R, Chaccour CJ, Rist C.BMJ Glob Health. 2021 Nov;6(11):e006424. doi: 10.1136/bmjgh-2021-006424.

24.Early-life exposure to Ivermectin alters long-term growth and disease susceptibility. McMahon TA, Fernandez-Denmark S, Grim JM.PLoS o­ne. 2021 Oct 13;16(10):e0258185. doi: 10.1371/journal.pone.0258185. eCollection 2021.PMID: 34644335.

25.Identification of the asymptomatic Plasmodium falciparum and Plasmodium vivax gametocyte reservoir under different transmission intensities.Koepfli C, Nguitragool W, de Almeida ACG, Kuehn A, Waltmann A, Kattenberg E, Ome-Kaius M, Rarau P, Obadia T, Kazura J, Monteiro W, Darcy AW, Wini L, Bassat Q, Felger I, Sattabongkot J, Robinson LJ, Lacerda M, Mueller I.PLoS Negl Trop Dis. 2021 Aug 27;15(8):e0009672. doi: 10.1371/journal.pntd.0009672. eCollection 2021 Aug.PMID: 34449764.

26.The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries.Trunfio M, Scabini S, Mornese Pinna S, Rugge W, Alcantarini C, Pirriatore V, Di Perri G, Bonora S, Castelnuovo B, Calcagno A.Microorganisms. 2021 Jul 31;9(8):1648. doi: 10.3390/microorganisms9081648.PMID: 34442727.16

27.Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?Turner HC, Stolk WA, Solomon AW, King JD, Montresor A, Molyneux DH, Toor J.BMJ Glob Health. 2021 Aug;6(8):e005456. doi: 10.1136/bmjgh-2021-005456.PMID: 34385158.

28.Broadening the range of use cases for ivermectin - a review of the evidence.Kositz C, Bradley J, Hutchins H, Last A, D'Alessandro U, Marks M.Trans R Soc Trop Med Hyg. 2022 Mar 2;116(3):201-212. doi: 10.1093/trstmh/trab114.PMID: 34323283 

29.The effect of cattle-administered ivermectin and fipronil o­n the mortality and fecundity of Anopheles arabiensis Patton.Makhanthisa TI, Braack L, Lutermann H.Parasit Vectors. 2021 Jul 2;14(1):349. doi: 10.1186/s13071-021-04846-8.PMID: 34215295. 

30.Ivermectin treatment in humans for reducing malaria transmission.de Souza DK, Thomas R, Bradley J, Leyrat C, Boakye DA, Okebe J.Cochrane Database Syst Rev. 2021 Jun 29;6(6):CD013117. doi: 10.1002/14651858.CD013117.pub2.PMID: 34184757 

31.From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia.Fehr A, Nieto-Sanchez C, Muela J, Jaiteh F, Ceesay O, Maneh E, Baldeh D, Achan J, Dabira E, Conteh B, Bunders-Aelen J, Smekens T, Broekhuizen H, D'Alessandro U, Peeters Grietens K.Malar J. 2021 Apr 26;20(1):198.

32.Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure.Thriemer K, Ley B, von Seidlein L.PLoS Med. 2021 Apr 23;18(4):e1003494. doi: 10.1371/journal.pmed.1003494. eCollection 2021 Apr.

33.A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?Jittamala P, Monteiro W, Smit MR, Pedrique B, Specht S, Chaccour CJ, Dard C, Del Giudice P, Khieu V, Maruani A, Failoc-Rojas VE, Sáez-de-Ocariz M, Soriano-Arandes A, Piquero-Casals J, Faisant A, Brenier-Pinchart MP, Wimmersberger D, Coulibaly JT, Keiser J, Boralevi F, Sokana O, Marks M, Engelman D, Romani L, Steer AC, von Seidlein L, White NJ, Harriss E, Stepniewska K, Humphreys GS, Kennon K, Guerin PJ, Kobylinski KC.PLoS Negl Trop Dis. 2021 Mar 17;15(3):e0009144. doi: 10.1371/journal.pntd.0009144. eCollection 2021 Mar.PMID: 33730099 

34.High concentrations of membrane-fed ivermectin are required for substantial lethal and sublethal impacts o­n Aedes aegypti.Hadlett M, Nagi SC, Sarkar M, Paine MJI, Weetman D.Parasit Vectors. 2021 Jan 6;14(1):9. doi: 10.1186/s13071-020-04512-5.PMID: 33407825 

35.Targeting Malaria Hotspots to Reduce Transmission Incidence in Senegal. Sallah K, Giorgi R, Ba EH, Piarroux M, Piarroux R, Cisse B, Gaudart J.Int J Environ Res Public Health. 2020 Dec 24;18(1):76. doi: 10.3390/ijerph18010076.PMID: 33374228 

36.The use of islands and cluster-randomized trials to investigate vector control interventions: a case study o­n the Bijagós archipelago, Guinea-Bissau. Jones RT, Pretorius E, Ant TH, Bradley J, Last A, Logan JG.Philos Trans R Soc Lond B Biol Sci. 2021 Feb 15;376(1818):20190807. doi: 10.1098/rstb.2019.0807. Epub 2020 Dec 28.PMID: 33357055  

37.Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK.Lancet. 2019 Apr 13;393(10180):1517-1526. doi: 10.1016/S0140-6736(18)32321-3. Epub 2019 Mar 14.PMID: 30878222

38.Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control o­n the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones RT, Ndiath MO, Dit Massire Soumare H, Mabey D, Nante EJ, Martins C, Logan JG, Slater H, Drakeley C, D'Alessandro U, Rodrigues A, Last AR.BMJ Open. 2023 Jul 7;13(7):e072347. doi: 10.1136/bmjopen-2023-072347.PMID: 37419638.

39.Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet 2019;393(10180):1517-26.

40.Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015).

41.Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Alout H, Krajacich BJ, Meyers JI, Grubaugh ND, Brackney DE, Kobylinski KC, et al. Malaria Journal 2014;13:417. [DOI: 10.1186/1475-2875-13-417] - DOI - PMC - PubMed

42.Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Bockarie MJ, Alexander ND, Hyun P, Dimber Z, Bockarie F, Ibam E, et al. Lancet 1998;351(9097):162-8. [DOI: 10.1016/S0140-6736(97)07081-5]

43.Effect of ivermectin o­n Anopheles gambiae mosquitoes fed o­n humans: the potential of oral insecticides in malaria control. Chaccour C, Lines J, Whitty CJ. Journal of Infectious Diseases 2010;202(1):113-6.

44.Differential effect of human ivermectin treatment o­n blood feeding Anopheles gambiae and Culex quinquefasciatus. Derua YA, Kisinza WN, Simonsen PE. Parasites & Vectors 2015;8:130.

45.Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: Study protocol for a cluster randomised controlled trial. Souza DK, Ahorlu CS, Adu-Amankwah S, Otchere J, Mensah SK, Larbi IA, et al. Trials 2017;18(1):448. doi: 10.1186/s13063-017-2196-9].

46.Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. American Journal of Tropical Medicine and Hygiene 2011;85(1):3-5. [DOI: 10.4269/ajtmh.2011.11-0160]

47.Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. Kobylinski KC, Ubalee R, Ponlawat A, Nitatsukprasert C, Phasomkulsolsil S, Wattanakul T, et al. Malaria Journal 2017;16(1):280. [DOI: 10.1186/s12936-017-1923-8].

48.Incidental mosquitocidal effect of an ivermectin mass drug administration o­n Anopheles farauti conducted for scabies control in the Solomon Islands. Kositz C, Talina J, Diau J, Asugeni R, Whitehorn C, Mabey D, et al. Transactions of the Royal Society of Tropical Medicine and Hygiene 2017;111(3):97-101.

49.The effect of ivermectin® o­n fertility, fecundity and mortality of Anopheles arabiensis fed o­n treated men in Ethiopia. Mekuriaw W, Balkew M, Messenger LA, Yewhalaw D, Woyessa A, Massebo F. Malaria Journal 2019;18(1):537. doi: 10.1186/s12936-019-2988-3.

50.Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: A double-blind, randomized, clinical trial. Quédraogo AL, Bastiaens GJ, Tiono AB, Guelbéogo WM, Kobylinski KC, Ouédraogo A, et al. Clinical Infectious Diseases 2015;60(3):357-65.

51.Promising approach to reducing Malaria transmission by ivermectin: sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. Pinilla YT, Lopes SCP, Sampaio VS, Andrade FS, Melo GC, Orfanó AS, et al. PLoS Neglected Tropical Diseases 2018;12(2):e0006221.

52.Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, et al. Lancet Infected Diseases 2016;18(6):615-26.

53.The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. European Journal of Clinical Pharmacology 1988;35(6):681-4. - PubMed

54.Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. Eldridge S, Campbell M, Campbell M, Drahota A, Giraudeau B, Higgins J, et al. https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool (2021).

55.Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with o­nchocerca volvulus. Elkassaby MH. Tropical Medicine and Parasitology 1991;42(2):79-81.

56.The potential of ivermectin to control the malaria vector Anopheles farauti. Foley DH, Bryan JH, Lawrence GW. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000;94(6):625-8.

57.Gardon J, Gardon-Wendel N, Ngangue D, Kamgno J, Chippaux J-P, Boussinesq M. Serious reactions after mass treatment of o­nchocerciasis with ivermectin in an area endemic for Loa loa. Lancet 1997;350(9070):18-20

58.The pharmacokinetics and interactions of ivermectin in humans - a mini-review. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. American Association of Pharmaceutical Scientists Journal 2008;10(1):42-6.

59.Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy. Ikeda T. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 2003;122(6):527-38

60.The Ivermectin Roadmappers. A roadmap for the development of ivermectin as a complementary malaria vector control tool. Billingsley P, Binka F, Chaccour C, Foy B, Gold S, Gonzalez-Silva M, et al, American Journal of Tropical Medicine and Hygiene 2020;102(2s):3-24.

61.. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. Meyers JI, Gray M, Kuklinski W, Johnson LB, Snow CD, Black WC 4th, et al. Journal of Experimental Biology 2015;218(Pt 10):1478-86.

62.Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, et al. Lancet Global Health 2020;8(1):e92-100.

63.Multiple insecticide resistance in the major malaria vector Anopheles funestus in southern Ghana: implications for malaria control. Riveron JM, Osae M, Egyir-Yawson A, Irving H, Ibrahim SS, Wondji CS. Parasites & Vectors 2016;9(1):504.

64.Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, et al. Malaria Journal 2010;9:365.

65.Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Tesh RB, Guzman H. American Journal of Tropical Medicine and Hygiene 1990;43(3):229-33.

66.World Health Organization. WHO preferred product characteristics: endectocide for malaria transmission control. 2018.

67.World Health Organziation. Ivermectin for malaria transmission control: Technical consultation meeting report. www.who.int/malaria/mpac/mpac-sept2016-invermectin-session9.pdf?

68.Ivermectin treatment in humans for reducing malaria transmission. Souza DK, Larbi I, Boakye DA, Okebe J. Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No: CD013117.

Các nội dung khác »

---